ESR1 and breast carcinoma: In estrogen receptor–positive (ER+) breast cancer, a notable example is circTNK2, which has been therapeutically targeted using nanoparticles co-loaded with antisense oligonucleotides (ASOs) and immunomodulatory CXCL10 plasmids (101).